- Home
- SAN vs AZN Comparison
SAN vs AZN Comparison
Compare SAN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | AZN |
|---|---|---|
| Founded | 1857 | 1992 |
| Country | Spain | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.8B | 285.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SAN | AZN |
|---|---|---|
| Price | $11.47 | $195.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 16.1M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.67% | 1.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.83 | $10.13 |
| Revenue Next Year | $5.67 | $6.21 |
| P/E Ratio | ★ $11.21 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.54 | $61.24 |
| 52 Week High | $13.24 | $212.71 |
Technical Indicators
Market Signals| Indicator | SAN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 62.31 |
| Support Level | $9.84 | $89.28 |
| Resistance Level | $13.17 | $211.32 |
| Average True Range (ATR) | 0.37 | 3.22 |
| MACD | -0.14 | -5.21 |
| Stochastic Oscillator | 30.16 | 25.10 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.